S&P 500   4,962.34 (-0.97%)
DOW   37,949.95 (+0.46%)
QQQ   414.51 (-2.10%)
AAPL   165.14 (-1.14%)
MSFT   399.39 (-1.21%)
META   481.55 (-4.04%)
GOOGL   154.02 (-1.28%)
AMZN   174.44 (-2.67%)
TSLA   147.17 (-1.84%)
NVDA   771.94 (-8.83%)
AMD   146.41 (-5.59%)
NIO   3.81 (-4.75%)
BABA   69.00 (+0.17%)
T   16.45 (+0.73%)
F   12.10 (+0.33%)
MU   106.73 (-4.65%)
GE   148.36 (-2.99%)
CGC   7.99 (+2.04%)
DIS   112.20 (-0.20%)
AMC   3.19 (+9.25%)
PFE   25.97 (+2.28%)
PYPL   61.99 (-0.18%)
XOM   119.75 (+1.04%)
S&P 500   4,962.34 (-0.97%)
DOW   37,949.95 (+0.46%)
QQQ   414.51 (-2.10%)
AAPL   165.14 (-1.14%)
MSFT   399.39 (-1.21%)
META   481.55 (-4.04%)
GOOGL   154.02 (-1.28%)
AMZN   174.44 (-2.67%)
TSLA   147.17 (-1.84%)
NVDA   771.94 (-8.83%)
AMD   146.41 (-5.59%)
NIO   3.81 (-4.75%)
BABA   69.00 (+0.17%)
T   16.45 (+0.73%)
F   12.10 (+0.33%)
MU   106.73 (-4.65%)
GE   148.36 (-2.99%)
CGC   7.99 (+2.04%)
DIS   112.20 (-0.20%)
AMC   3.19 (+9.25%)
PFE   25.97 (+2.28%)
PYPL   61.99 (-0.18%)
XOM   119.75 (+1.04%)
S&P 500   4,962.34 (-0.97%)
DOW   37,949.95 (+0.46%)
QQQ   414.51 (-2.10%)
AAPL   165.14 (-1.14%)
MSFT   399.39 (-1.21%)
META   481.55 (-4.04%)
GOOGL   154.02 (-1.28%)
AMZN   174.44 (-2.67%)
TSLA   147.17 (-1.84%)
NVDA   771.94 (-8.83%)
AMD   146.41 (-5.59%)
NIO   3.81 (-4.75%)
BABA   69.00 (+0.17%)
T   16.45 (+0.73%)
F   12.10 (+0.33%)
MU   106.73 (-4.65%)
GE   148.36 (-2.99%)
CGC   7.99 (+2.04%)
DIS   112.20 (-0.20%)
AMC   3.19 (+9.25%)
PFE   25.97 (+2.28%)
PYPL   61.99 (-0.18%)
XOM   119.75 (+1.04%)
S&P 500   4,962.34 (-0.97%)
DOW   37,949.95 (+0.46%)
QQQ   414.51 (-2.10%)
AAPL   165.14 (-1.14%)
MSFT   399.39 (-1.21%)
META   481.55 (-4.04%)
GOOGL   154.02 (-1.28%)
AMZN   174.44 (-2.67%)
TSLA   147.17 (-1.84%)
NVDA   771.94 (-8.83%)
AMD   146.41 (-5.59%)
NIO   3.81 (-4.75%)
BABA   69.00 (+0.17%)
T   16.45 (+0.73%)
F   12.10 (+0.33%)
MU   106.73 (-4.65%)
GE   148.36 (-2.99%)
CGC   7.99 (+2.04%)
DIS   112.20 (-0.20%)
AMC   3.19 (+9.25%)
PFE   25.97 (+2.28%)
PYPL   61.99 (-0.18%)
XOM   119.75 (+1.04%)
Free Trial
NASDAQ:VBLT

Vascular Biogenics (VBLT) Stock Price, News & Analysis

→ Strange new buyer driving up gold (From Stansberry Research) (Ad)
Free VBLT Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$5.34
▼
$6.74
50-Day Range
$0.16
▼
$5.46
52-Week Range
$0.10
▼
$6.74
Volume
161,505 shs
Average Volume
2.19 million shs
Market Capitalization
$423.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
VBLT stock logo

About Vascular Biogenics Stock (NASDAQ:VBLT)

Vascular Biogenics Ltd., a biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. It develops VB-601 using monocyte targeting technology for various inflammatory indications. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel.

VBLT Stock News Headlines

November 3, 2023 | msn.com
Vascular Biogenics (VBLT) Price Target Increased by 160.00% to 13.26
October 16, 2023 | finance.yahoo.com
Notable Labs Closes Merger Transaction With VBL Therapeutics
April 19, 2024 | Gold Safe Exchange (Ad)
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
October 12, 2023 | finance.yahoo.com
VBL Therapeutics Announces Results of Annual and Special Shareholder Meeting
October 4, 2023 | finance.yahoo.com
VBL Therapeutics Reminds Shareholders to Vote in the Upcoming Annual and Special Shareholder Meeting
September 9, 2023 | finance.yahoo.com
Vascular Biogenics Rises on Presentation Hype
September 6, 2023 | finance.yahoo.com
VBL Therapeutics Announces that S-4 Registration Statement for Proposed Merger with Notable Labs Is Declared Effective by SEC
August 28, 2023 | businesswire.com
VASCULAR BIOGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vascular Biogenics Ltd. - VBLT
April 19, 2024 | Gold Safe Exchange (Ad)
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
August 28, 2023 | businesswire.com
VASCULAR BIOGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vascular Biogenics Ltd. - VBLT
August 14, 2023 | finance.yahoo.com
VBL Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
July 23, 2023 | fool.com
Vascular Biogenics (NASDAQ: VBLT)
May 15, 2023 | finance.yahoo.com
VBL Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
April 4, 2023 | benzinga.com
Vascular Biogenics Stock (NASDAQ:VBLT), Dividends
March 17, 2023 | finance.yahoo.com
Vascular Biogenics Full Year 2022 Earnings: US$0.42 loss per share (vs US$0.45 loss in FY 2021)
March 14, 2023 | finance.yahoo.com
VBL Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update
March 9, 2023 | finance.yahoo.com
VBL Therapeutics Announces Closing of Sale of Manufacturing Facility and Certain Related Assets for $7.1 Million in Cash
February 27, 2023 | prnewswire.com
SHAREHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Vascular Biogenics Ltd. - VBLT
February 23, 2023 | technews.tmcnet.com
VBLT STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Merger of Vascular Biogenics Ltd. Is Fair to Shareholders
February 23, 2023 | benzinga.com
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Vascular Biogenics Ltd. Merger
February 23, 2023 | marketwatch.com
Vascular Biogenics Shares Jump Premarket on Reverse Merger Plans >VBLT
February 23, 2023 | msn.com
Vascular Biogenics rises 85% on all-stock merger deal with Notable Labs
February 23, 2023 | investorplace.com
Why Is Vascular Biogenics (VBLT) Stock Up 52%?
February 16, 2023 | finance.yahoo.com
VBL Therapeutics Announces Agreement to Sell Manufacturing Facility and Certain Related Assets for $7.1 Million in Cash
November 10, 2022 | finance.yahoo.com
OYSTER PT PHARM (OYST) Reports Q3 Loss, Lags Revenue Estimates
September 2, 2022 | finance.yahoo.com
Axsome (AXSM) Starts Late-Stage Study of Migraine Drug AXS-07
September 1, 2022 | finance.yahoo.com
VBL Therapeutics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
See More Headlines
Receive VBLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vascular Biogenics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2021
Today
4/19/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:VBLT
Previous Symbol
NASDAQ:VBLX
CUSIP
N/A
CIK
1603207
Web
www.vblrx.com
Phone
(728) 993-5000
Fax
972-8993-5001
Employees
7
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($0.21)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-32,300,000.00
Net Margins
N/A
Pretax Margin
-3,317.05%
Return on Equity
-73.45%
Return on Assets
-54.11%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.63
Quick Ratio
4.63

Sales & Book Value

Annual Sales
$660,000.00
Price / Sales
642.29
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.32 per share
Price / Book
17.06

Miscellaneous

Outstanding Shares
77,640,000
Free Float
72,881,000
Market Cap
$423.91 million
Optionable
Optionable
Beta
0.77
A Guide To High-Short-Interest Stocks Cover
A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Prof. Dror Harats M.D. (Age 66)
    CEO & Director
    Comp: $444.33k
  • Mr. Samuel Backenroth (Age 39)
    Chief Financial Officer
    Comp: $410k
  • Dr. Eyal Breitbart Ph.D. (Age 56)
    Sr. VP of Research & Operations
  • Advocate Ayelet Horn (Age 52)
    Gen. Counsel
  • Dr. Erez Feige M.B.A. (Age 49)
    Ph.D., Sr. VP of Bus. Operations

Key Competitors

View All Competitors

VBLT Stock Analysis - Frequently Asked Questions

How were Vascular Biogenics' earnings last quarter?

Vascular Biogenics Ltd. (NASDAQ:VBLT) released its earnings results on Monday, November, 15th. The biopharmaceutical company reported ($0.09) EPS for the quarter, beating analysts' consensus estimates of ($0.11) by $0.02. The biopharmaceutical company had revenue of $0.20 million for the quarter, compared to the consensus estimate of $0.20 million. During the same period in the prior year, the company posted ($0.12) EPS.

What other stocks do shareholders of Vascular Biogenics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vascular Biogenics investors own include SCYNEXIS (SCYX), Matinas BioPharma (MTNB), OPKO Health (OPK), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Aeterna Zentaris (AEZS), Dynavax Technologies (DVAX), Vaxart (VXRT) and Geron (GERN).

This page (NASDAQ:VBLT) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
The “Perfect Storm” for Gold
Gold Safe Exchange
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
Biden’s $374B Giveaway Into This Sector
DTI
Your Money is Not Safe
American Alternative
He Is Giving Away Bitcoin
Crypto Swap Profits
The #1 Crypto for 2024
InvestorPlace
SHOCKING Crypto Leak…
Crypto 101 Media
My biggest AI fear
Paradigm Press